Search Videos and More
Venetoclax Added to Chemotherapy Improves Outcomes in Type of Leukemia
Adding the BCL-2 inhibitor drug venetoclax to a combination chemotherapy regimen significantly improved outcomes in Richter’s syndrome, a rare but deadly complication that develops in some patients with chronic lymphocytic leukemia (CLL), according to a study led by Dana-Farber investigators.2021 SABCS Highlights
Dana-Farber Cancer Institute faculty highlights from the 2021 San Antonio Breast Cancer Symposium.Immunotherapy Combination Shows Significant Benefit for Patients with Advanced Melanoma
A combination of two drugs that target different proteins on immune system T cells kept advanced melanoma in check significantly longer than one of the drugs alone in a phase 3 clinical trial involving 714 patients.Blood Cancer Research: Clinical Trial Helps Younger Patient
A patient shares her journey getting diagnosed with chronic lymphocytic leukemia in her 30's. Dana-Farber Cancer Institute's Matthew Davids, MD, MMSc, enrolled her on a clinical trial and details the results of that study. The research is now getting presented at ASH21.Inadequate SARS-COV-2 Vaccine Effectiveness in Patients with Multiple Myeloma: A Large Nationwide Veterans Affairs Study
Dana-Farber Cancer Institute's Nikhil C. Munshi, MD, details study looking at COVID-19 vaccine effectiveness in patients with multiple myeloma. Research presented at ASH21.ASH 2021 Highlights - CME
Register for 2021 ASH Highlights CMENew Study Reveals Elevated Rates of Blood Cancer Precursor Condition in Groups at High Risk for Multiple Myeloma
Dana-Farber Cancer Institute research shows elevated rates of a blood cancer precursor condition in groups at high risk for multiple myeloma.Study of Fully Vaccinated Patients with Cancer who had Breakthrough COVID-19 Shows 13% Mortality Rate
The first study to evaluate the clinical characteristics and outcomes of fully vaccinated patients with cancer who had breakthrough COVID-19 infections indicates they remained at high risk for hospitalization and death.COVID-19 and Cancer: Breakthrough Infections
New study: Fully vaccinated patients with cancer who had breakthrough COVID-19 infections remained at high risk for hospitalization and death. Dana-Farber's Toni Choueiri, MD, highlights the research.Blood Cancer Research: Clinical trial helps younger patient
Dr. Matthew Davids presented a study that demonstrated the ibrutinib+FCR drug combination keeps chronic lymphocytic leukemia in young patients in remission for several years.COVID-19 vaccine and blood cancer
Dr. Nikhil Munshi and colleagues reported a study demonstrating that COVID-19 vaccination offers less protection for multiple myeloma patients, reinforcing the need for these patients to use additional precautions.Blood Cancer: Higher rates of precursor in high-risk individuals
Dr. Irene Ghobrial and Dr. Habib El-Khoury shared the first results from the Promise study, which screens individuals at high risk for multiple myeloma.